What Happened — and When

For more than two decades, hormone replacement therapy was one of the most fear-laden topics in women's healthcare. A 2002 study from the Women's Health Initiative triggered a collapse in HRT prescribing that affected an estimated 50 million women — and the black-box warnings that resulted remained in place long after the science had moved on.

In 2025, that began to change. Two events, four months apart, mark what may be the most significant shift in menopause care policy in a generation.

July 17, 2025
The FDA Expert Panel
The FDA convened a full-day expert panel at its White Oak campus in Silver Spring, Maryland, bringing together leading clinicians in gynecology, endocrinology, urology, cardiology, neuroscience, and orthopedics to reexamine the evidence on menopausal hormone therapy. The session was livestreamed publicly and represented the most substantive regulatory engagement with the HRT evidence base in over 20 years.
November 10, 2025
The FDA Acts
Following the panel, a scientific literature review, and a public comment period, HHS Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary announced the removal of broad black-box warnings from HRT products for menopause — including warnings for cardiovascular disease, breast cancer, and probable dementia. The announcement marked the end of a warning framework that the agency itself acknowledged was rooted in distorted risk interpretation.

The Study That Started It All — and Why It Was Misread

To understand why this moment matters, you have to understand what went wrong in 2002. The Women's Health Initiative study was a large, federally funded trial that was stopped early after researchers identified a nominally elevated risk of breast cancer in women taking a combined estrogen-progestin regimen. The headlines were immediate and alarming. Prescriptions collapsed. Women stopped treatment mid-course. A generation of providers became reluctant to prescribe hormones at all.

What the headlines didn't convey — and what the July 2025 FDA panel addressed directly — was that the WHI had several critical limitations that made its findings poorly applicable to most menopausal women seeking treatment today.

The average age of women enrolled in the WHI was 63 — more than a decade past the average age of menopause onset. Many were obese or had pre-existing cardiovascular risk factors. The formulation studied — oral conjugated equine estrogens combined with medroxyprogesterone acetate — is not the same as the bioidentical estradiol and micronized progesterone commonly prescribed today. And critically, the study's own authors would later confirm that for women under 60, or within 10 years of menopause onset, the data showed a different picture entirely.

"Tragically, tens of millions of women have been denied the long-term health benefits of hormone replacement therapy because of a medical dogma rooted in a distortion of risk."

FDA Commissioner Marty Makary, MD, MPH — November 10, 2025

What the Experts Said

The July panel brought together some of the most prominent voices in menopause research. What follows are the key arguments made — grounded in the evidence presented on the day and in the research it drew from.

Howard N. Hodis, MD — University of Southern California
"We have 50 years of data. These data should be followed — not just the data that gives us the particular outcomes we want to believe, but all of the data."
Hodis presented the cardiovascular evidence, including data showing a 25–50% reduction in fatal heart attacks and cardiovascular disease when hormone therapy is initiated within 10 years of menopause — a risk reduction he noted is comparable to, or greater than, what statins provide.
JoAnn Pinkerton, MD, FACOG, MSCP — University of Virginia
"The boxed warning is not supported by science. It harms women. It reflects a class labeling extrapolated from the WHI trial. It overstates risk. There is an absence of any randomized trial or consistent observational evidence linking vaginal estrogen for GSM to cancer, heart disease, dementia, blood clots, or stroke."
Pinkerton presented a 2025 systematic review published in the American Journal of Obstetrics and Gynecology showing that women with a history of breast cancer who used vaginal hormone therapy had no increased risk of cancer recurrence compared to controls — directly contradicting the basis for the vaginal estrogen black-box warning.
Heather Hirsch, MD — Internist, Panel Member
"Vaginal or local estrogen is categorically safe for all women, period. Because it does not travel systemically, there are no increased risks of heart attacks, clots, or strokes. The black box warning is wrong."
Hirsch distinguished clearly between local vaginal estrogen — which stays in the tissue where it's applied and does not reach measurable blood concentrations — and systemic hormone therapy. The two have been treated as equivalent by the warning language for over two decades, causing widespread avoidance of a treatment with a well-established local safety profile.
Roberta Diaz Brinton, PhD — University of Arizona
Brinton presented imaging and mechanistic research linking the menopausal transition to early Alzheimer's disease pathology, describing estrogen as a "master regulator" of brain function. Her research suggests that timely initiation of hormone therapy may meaningfully reduce neurodegenerative risk — and that the timing of when HRT begins relative to menopause onset is a critical variable that the original WHI did not adequately account for.
Vonda Wright, MD — Orthopedic Surgeon, University of Central Florida
"It is estimated that estrogen must be used for 10 years to change the outcome of fracture — and that once you stop estrogen, your bone will rapidly decline as if you'd never had it at all."
Wright brought the orthopedic perspective: estrogen's protective effect on bone density is well established, but it requires consistent, long-term use to translate into meaningful fracture risk reduction. The "lowest effective dose for the shortest duration" guidance that had been embedded in HRT labeling was, she argued, directly undermining the treatment's most clinically significant benefit.

The Numbers That Matter

The FDA's November 2025 announcement cited specific risk reduction figures drawn from randomized studies — data that had been available for years but had been obscured by the fear framework created by the original WHI reporting.

50%
Potential reduction in cardiovascular disease risk when HRT is initiated within 10 years of menopause onset
35%
Potential reduction in Alzheimer's disease risk associated with appropriately timed hormone therapy
50–60%
Potential reduction in bone fracture risk with sustained estrogen therapy — contingent on long-term use

These figures come from the FDA's own November 2025 press release, citing randomized study data. They represent the potential benefits that were consistently underweighted in the warning framework women and their providers had been working within for more than two decades.

What the FDA Actually Changed

FDA Action — November 10, 2025
Black-Box Warning Removal: What Was Removed and What Wasn't
  • Removed: Boxed warnings citing increased risk of cardiovascular disease and stroke from HRT labeling.
  • Removed: Boxed warnings citing increased risk of breast cancer from combined and estrogen-alone systemic HRT products.
  • Removed: Boxed warnings citing probable dementia risk from HRT labeling.
  • Removed: The blanket recommendation to prescribe at "the lowest effective dose for the shortest duration" — guidance that directly undermined HRT's bone and cardiovascular protective effects.
  • Added: Timing guidance recommending initiation within 10 years of menopause onset or before age 60 for systemic HRT, reflecting the "timing hypothesis" supported by the current evidence base.
  • Retained: The boxed warning for endometrial cancer in systemic estrogen-alone products for women with a uterus — this remains clinically supported and unchanged.
  • Approved: A generic version of Premarin — the first in over 30 years — expected to meaningfully improve affordability and access.
Source: FDA Press Release, November 10, 2025 — HHS Advances Women's Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy

A Special Note on Vaginal Estrogen

One of the clearest and most clinically urgent messages from the July panel was the consensus around local vaginal estrogen. This is the cream, ring, or suppository form of estrogen used to treat genitourinary syndrome of menopause (GSM) — vaginal dryness, painful intercourse, tissue thinning, and recurrent urinary tract infections caused by estrogen deficiency in the local tissue.

Unlike systemic HRT, local vaginal estrogen does not enter the bloodstream in clinically meaningful amounts. It works where it's applied. The black-box warning it carried — identical to the warning on systemic hormones — had been extrapolated from WHI data on a completely different route of administration, in a completely different population. Panel members were unambiguous: the warning caused direct patient harm. Women avoided a safe, effective local treatment because the label said "cancer risk" — and their providers, reading the same label, often agreed with their hesitation.

The topical vaginal estrogen labeling has now been updated to reflect the safety findings relevant to local use specifically — separating it, at last, from the systemic hormone risk language it never should have shared.

What This Means If You're a Patient in Nevada Today

Practical Implications
  • The black-box warnings that made many providers hesitant to prescribe HRT have been removed. Conversations about hormone therapy should be easier to have — and more evidence-grounded — than they were even a year ago.
  • If you were previously told HRT was "too risky" without a thorough discussion of your individual risk profile, that conversation deserves to be revisited. The regulatory landscape that framed that advice has fundamentally changed.
  • Vaginal estrogen for dryness, painful intercourse, or recurrent UTIs is now labeled accurately. It is not a systemic risk. If your provider has been reluctant to prescribe it for that reason, point them to the updated labeling.
  • The "lowest dose, shortest duration" guidance has been removed from labeling. For women where sustained HRT provides meaningful protection — against fracture, cardiovascular events, or cognitive decline — long-term therapy is now more clearly supported by the regulatory framework.
  • Timing still matters. The updated labeling recommends initiating systemic HRT within 10 years of menopause onset or before age 60 to optimize benefit-risk balance. If you're approaching or past that window, a nuanced conversation with a knowledgeable provider is essential — not a blanket refusal.

At Xena Health, Cherie Little holds the Menopause Society Certified Practitioner (MSCP) credential — one of a small number of providers in the Henderson and Las Vegas area with formal, current credentialing in menopause care. The MSCP credential requires demonstrated knowledge of exactly the evidence base discussed at this panel: the timing hypothesis, the distinction between formulations, the role of local vs. systemic estrogen, and the individualized risk-benefit conversation every menopausal woman deserves to have.

If you've been managing symptoms without adequate support, or if past conversations about HRT left you more confused than informed, we'd like to offer a different kind of visit.

Watch the Full FDA Panel — July 17, 2025
The Conversation Has Changed
Book a Consultation with an MSCP-Credentialed Provider

Cherie Little is one of a small number of Menopause Society Certified Practitioners in the Henderson and Las Vegas area. A 45-minute visit includes a full hormonal evaluation, lab review, and a treatment plan based on your individual risk profile — not the old warning framework.

Book a Consultation